- Home
- NTRA vs BMRN Comparison
NTRA vs BMRN Comparison
Compare NTRA & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- BMRN
- Stock Information
- Founded
- NTRA 2003
- BMRN 1996
- Country
- NTRA United States
- BMRN United States
- Employees
- NTRA N/A
- BMRN 3401
- Industry
- NTRA Medical Specialities
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NTRA Health Care
- BMRN Health Care
- Exchange
- NTRA Nasdaq
- BMRN Nasdaq
- Market Cap
- NTRA 13.7B
- BMRN 16.1B
- IPO Year
- NTRA 2015
- BMRN 1999
- Fundamental
- Price
- NTRA $129.95
- BMRN $70.75
- Analyst Decision
- NTRA Strong Buy
- BMRN Buy
- Analyst Count
- NTRA 15
- BMRN 20
- Target Price
- NTRA $123.64
- BMRN $109.37
- AVG Volume (30 Days)
- NTRA 1.2M
- BMRN 1.7M
- Earning Date
- NTRA 11-06-2024
- BMRN 10-30-2024
- Dividend Yield
- NTRA N/A
- BMRN N/A
- EPS Growth
- NTRA N/A
- BMRN 154.24
- EPS
- NTRA N/A
- BMRN 1.33
- Revenue
- NTRA $1,360,503,000.00
- BMRN $2,588,398,000.00
- Revenue This Year
- NTRA $42.99
- BMRN $18.10
- Revenue Next Year
- NTRA $13.11
- BMRN $11.17
- P/E Ratio
- NTRA N/A
- BMRN $63.61
- Revenue Growth
- NTRA 46.13
- BMRN 15.83
- 52 Week Low
- NTRA $36.90
- BMRN $73.68
- 52 Week High
- NTRA $128.28
- BMRN $99.56
- Technical
- Relative Strength Index (RSI)
- NTRA 66.43
- BMRN 21.66
- Support Level
- NTRA $114.62
- BMRN $83.43
- Resistance Level
- NTRA $118.52
- BMRN $85.64
- Average True Range (ATR)
- NTRA 4.62
- BMRN 2.43
- MACD
- NTRA 0.87
- BMRN -1.42
- Stochastic Oscillator
- NTRA 99.77
- BMRN 4.56
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.